Sentence: In the APHINITY study ( NCT01358877 , BIG 4 - 11/BO25126/TOC4939 G ) , pertuzumab added to trastuzumab and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer .
Drug combination annotation:
[{'class': 'POS', 'spans': ['pertuzumab', 'trastuzumab'], 'is_context_needed': False}]